ArticleCardiovascular research2024
Beyond the numbers in treating hypertensive end-organ damage: role of formyl peptide receptor agonist Cmpd17b.
Claude F Albritton, Antentor Hinton, Annet Kirabo
Abstract readEditorial
In one paragraphArticle in Cardiovascular research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
3 authors.
Claude F AlbrittonDivision of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, 560 Preston Cancer Research Building, 2220 Pierce Ave, Nashville, TN 37232, USA.
Antentor HintonDepartment of Molecular Physiology & Biophysics, Vanderbilt University, 750 Robinson Research Building, 2200 Pierce Ave, Nashville, TN 37232-0615, USA.ORCID 0000-0002-7730-952X Annet KiraboDivision of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, 560 Preston Cancer Research Building, 2220 Pierce Ave, Nashville, TN 37232, USA.ORCID 0000-0001-8580-9359 Funding
PRIDE: Functional and Translational Genomics of Blood DisordersR25HL106365 · NHLBI · AUGUSTA UNIVERSITY · PI PACE, BETTY SUE · 2010 to 2024
$5.2MMOLECULAR PARASITOLOGY TRAINING PROGRAMT32AI007281 · NIAID · MEHARRY MEDICAL COLLEGE · PI NDE, PIUS N · 1985 to 2025
$3.2MImmune Mechanisms of Salt-Sensitive hypertensionR01HL144941 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KIRABO, ANNET · 2021 to 2025
$3.0MBurroughs Wellcome FundChan Zuckerberg Initiative's Donor-Advised FundNHLBI NIH HHS R01 HL144941NHLBI NIH HHS R25 HL106365NIAID NIH HHS T32 AI007281NIH HHS D34HP16299NIH HHS R01HL144941NIH HHS T32AI007281NIH HHS T32GM14492NIH HHS T32HL00773Science Diversity Leadership 2022-253529Scientific Interface 1021868.01Silicon Valley Community FoundationThe UNCF/Bristol-Myers Squibb E.E. Just Faculty Fund
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
HypertensionReceptors, Formyl PeptideAnimalsAntihypertensive AgentsBlood PressureHumansSignal TransductionAntihypertensive AgentsReceptors, Formyl Peptide
Identifiers
PMID38980770
PMCPMC11416055
What OpenQuestion holds
Textmetadata
Read underepoch 390